Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
F&G: 35
5.524,83 S&P · 23,75 Vola-Index · 94.807,51 BTC · 1,14223 EURUSD
System-State: Number of processed items 39.539 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US03168L1052
State: 28.04.2025 | 6PM
Do you already know our new terminal view? Click here.
FIGI: BBG00462PGG0
AMRX
Amneal Pharmaceuticals Inc.
GICS: - · Sector: Drugs · Sub-Sector: -
NAME
Amneal Pharmaceuticals Inc.
ISIN
US03168L1052
TICKER
AMRX
MIC
XNAS
REUTERS
AMRX.OQ
BLOOMBERG
AMRX US
Fri, 11.04.2025       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced donations totaling $1.5 million to multiple patient assistance foundations that support individuals living with Parkinson’s disease in honor of Parkinson’s Awareness Month. These contributions underscore Amneal's ongoing com...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Tue, 08.04.2025       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its first quarter 2025 financial results on Friday, May 2, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be acc...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Mon, 07.04.2025       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced a new analysis of the pivotal RISE-PD Phase 3 study showed that patients who successfully converted to CREXONT from immediate release (IR) carbidopa/levodopa (CD/LD) experienced statistically significant improvements in slee...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Thu, 03.04.2025       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that three large insurance coverage accounts, the Veterans Administration (VA), UnitedHealthcare and CVS Health, have added CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Tue, 01.04.2025       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and Shilpa Medicare Limited (“Shilpa”) today announced the U.S. launch of BORUZU™, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV) administration. This new ready-to-use oncology product redu...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Mon, 10.03.2025       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will present at the Barclays 27th Annual Global Healthcare Conference on March, 12, 2025. Chirag Patel, Co-Chief Executive Officer and President, will participate in a fireside chat at 11:00 AM ET. A live webcast of the fireside chat will be accessible on the Company's website at https://investors.amneal...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Mon, 03.03.2025       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and mAbxience (“mAbxience”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics Licensing Application (BLA) for two proposed denosumab biosimilars referencing Prolia® and XGEVA®. mAbxience ...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Fri, 28.02.2025       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December 31, 2024. “Amneal’s continued success in 2024 demonstrates our ability to drive sustainable growth through disciplined execution, continuous innovation, and strategic capital allocation. All thre...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Wed, 19.02.2025       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment of moderately active ulcerative colitis in adults. Additionally, the Company has received approval from the U.S. Food an...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Wed, 29.01.2025       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and li...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Thu, 23.01.2025       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved memantine/donepezil 14-10 mg and 28-10 mg extended-release capsules, which references Abbvie’s NAMZARIC®, and Everolimus 2 mg, 3 mg and 5 mg extended-release capsules, which references Novartis’ AFIN...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Wed, 04.12.2024       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in two upcoming investor conferences. 36th Annual Piper Sandler Annual Healthcare Conference December...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Thu, 21.11.2024       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, today announced the advancement of two key strategic initiatives. First, the Company has resubmitted to the U.S. Food and Drug Administration (FDA) its new drug application (NDA) for dihydroergotamine (DHE) prefilled syringe autoinjector for t...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Fri, 08.11.2024       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the third quarter ended September 30, 2024. “Q3 was an excellent quarter where we continued to drive strong financial results across our diversified business and we announced three strategic actions to solidify our long-term growth. First, we l...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Mon, 21.10.2024       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company based in the U.S., today announced that it has received U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for Pyridostigmine Bromide Extended-Release (PB ER) Tablets USP 105 mg. PB ER 105 mg tablets are a once-...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Tue, 08.10.2024       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. The financial results and live webcast will be acces...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Tue, 01.10.2024       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, and Metsera, Inc. (“Metsera”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that they have entered into a collaboration agreement to enable the eff...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Mon, 23.09.2024       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has launched CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease. CREXONT® is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release granules and extended-release pel...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Thu, 05.09.2024       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) and Shilpa Medicare Limited (“Shilpa”) announced U.S. Food and Drug Administration (FDA) approval of BORUZU™, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV) administration. This new ready-to-use oncology product reduces the co...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink
Tue, 20.08.2024       Amneal Pharma
US03168L1052

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (“ANDA”) approval from the U.S. Food and Drug Administration (FDA) for Propofol Injectable Emulsion USP, 200 mg/20 mL (10 mg/mL), 500 mg/50 mL (10 mg/mL), and 1,000 mg/100 mL (10 mg/mL), Single-Dose Vials. ...
Read More
Amneal Pharma
Technical Analysis Termsheet Terminal
Permalink

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.